Back to today’s briefing

Story perspectives

Supernus Pharmaceuticals to Acquire Sage for $795 Million

6/23/2025

25 2

Summary

Story summary

Supernus Pharmaceuticals is set to acquire Sage Therapeutics for up to $795 million, unlocking the potential of Zurzuvae, the groundbreaking oral treatment for postpartum depression. With an enticing $8.50 per share cash offer and additional value rights, this strategic move, anticipated to finalize in Q3 2025, promises to bolster Supernus's growth and streamline costs.

1 of 1

Story summary

Supernus Pharmaceuticals is set to acquire Sage Therapeutics for up to $795 million, unlocking the potential of Zurzuvae, the groundbreaking oral treatment for postpartum depression. With an enticing $8.50 per share cash offer and additional value rights, this strategic move, anticipated to finalize in Q3 2025, promises to bolster Supernus's growth and streamline costs.